These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36211215)

  • 1. Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs.
    Yamasaki H; Uematsu Y; Hayashi Y; Yamashita M; Tei M; Uchida K; Ono K; Hirao H
    Can J Vet Res; 2022 Oct; 86(4):286-293. PubMed ID: 36211215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
    Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H
    In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective detection of BRAF
    Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
    Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF
    Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
    Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
    PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
    Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K
    PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
    Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
    Kim JH; Ahn DH; Moon JS; Han HJ; Bae K; Yoon KA
    Vet Q; 2021 Dec; 41(1):153-162. PubMed ID: 33764261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
    Gedon J; Kehl A; Aupperle-Lellbach H; von Bomhard W; Schmidt JM
    Vet Comp Oncol; 2022 Jun; 20(2):449-457. PubMed ID: 34878687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of the COX2/PGE
    Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
    Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
    Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
    Mochizuki H; Breen M
    Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
    Karlou M; Saetta AA; Korkolopoulou P; Levidou G; Papanastasiou P; Boltetsou E; Isaiadis D; Pavlopoulos P; Thymara I; Thomas-Tsagli E; Patsouris E
    Pathology; 2009; 41(4):327-34. PubMed ID: 19404844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma.
    Mochizuki H; Shapiro SG; Breen M
    PLoS One; 2015; 10(12):e0144170. PubMed ID: 26649430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
    Parker HG; Dhawan D; Harris AC; Ramos-Vara JA; Davis BW; Knapp DW; Ostrander EA
    BMC Cancer; 2020 Mar; 20(1):251. PubMed ID: 32209086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.
    Kobayashi M; Onozawa M; Watanabe S; Nagashima T; Tamura K; Kubo Y; Ikeda A; Ochiai K; Michishita M; Bonkobara M; Kobayashi M; Hori T; Kawakami E
    Vet Comp Oncol; 2023 Jun; 21(2):221-230. PubMed ID: 36745053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
    Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
    Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.